Concepts (293)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Biomedical Research | 5 | 2025 | 502 | 1.450 |
Why?
|
| Cardiovascular Diseases | 8 | 2021 | 749 | 0.800 |
Why?
|
| Diabetes Mellitus, Type 1 | 5 | 2020 | 92 | 0.520 |
Why?
|
| Myopia | 8 | 2005 | 27 | 0.480 |
Why?
|
| Georgia | 8 | 2024 | 192 | 0.480 |
Why?
|
| Humans | 58 | 2025 | 43102 | 0.400 |
Why?
|
| Female | 40 | 2025 | 24698 | 0.350 |
Why?
|
| Eyeglasses | 7 | 2005 | 22 | 0.340 |
Why?
|
| Glaucoma, Open-Angle | 4 | 2003 | 83 | 0.340 |
Why?
|
| Visual Acuity | 8 | 2015 | 111 | 0.310 |
Why?
|
| Male | 37 | 2025 | 23409 | 0.300 |
Why?
|
| Adult | 21 | 2025 | 13872 | 0.290 |
Why?
|
| Residence Characteristics | 3 | 2021 | 363 | 0.290 |
Why?
|
| Resilience, Psychological | 2 | 2020 | 106 | 0.280 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2008 | 43 | 0.280 |
Why?
|
| Mentors | 3 | 2023 | 145 | 0.270 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2008 | 229 | 0.260 |
Why?
|
| Patient Compliance | 1 | 2008 | 233 | 0.250 |
Why?
|
| Middle Aged | 19 | 2025 | 12222 | 0.240 |
Why?
|
| Health Status Disparities | 3 | 2024 | 719 | 0.240 |
Why?
|
| Aged | 15 | 2025 | 8214 | 0.230 |
Why?
|
| Receptors, KIR | 2 | 2015 | 5 | 0.230 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2025 | 120 | 0.220 |
Why?
|
| Thyroidectomy | 2 | 2014 | 10 | 0.220 |
Why?
|
| Glucocorticoids | 2 | 2015 | 91 | 0.210 |
Why?
|
| Risk Assessment | 4 | 2020 | 863 | 0.210 |
Why?
|
| Disease Progression | 9 | 2008 | 667 | 0.210 |
Why?
|
| Killer Cells, Natural | 2 | 2015 | 104 | 0.210 |
Why?
|
| Intraocular Pressure | 4 | 2003 | 132 | 0.200 |
Why?
|
| Vision Tests | 1 | 2003 | 5 | 0.200 |
Why?
|
| Fathers | 1 | 2024 | 38 | 0.200 |
Why?
|
| Child | 15 | 2020 | 3443 | 0.200 |
Why?
|
| United States | 6 | 2025 | 5205 | 0.200 |
Why?
|
| Adolescent | 9 | 2023 | 6081 | 0.200 |
Why?
|
| Aged, 80 and over | 6 | 2023 | 2853 | 0.190 |
Why?
|
| Internet | 1 | 2024 | 236 | 0.190 |
Why?
|
| Minority Groups | 2 | 2025 | 690 | 0.190 |
Why?
|
| Breast Feeding | 1 | 2024 | 126 | 0.180 |
Why?
|
| Haplotypes | 2 | 2020 | 197 | 0.180 |
Why?
|
| Tropicamide | 1 | 2001 | 1 | 0.180 |
Why?
|
| Pupil | 1 | 2001 | 9 | 0.180 |
Why?
|
| Mydriatics | 1 | 2001 | 6 | 0.180 |
Why?
|
| Body Mass Index | 4 | 2021 | 925 | 0.180 |
Why?
|
| Young Adult | 6 | 2024 | 5080 | 0.170 |
Why?
|
| Diploidy | 2 | 2020 | 6 | 0.170 |
Why?
|
| Public Health | 1 | 2025 | 424 | 0.170 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2021 | 95 | 0.160 |
Why?
|
| Double-Blind Method | 7 | 2014 | 317 | 0.160 |
Why?
|
| Lactobacillus acidophilus | 2 | 2010 | 3 | 0.160 |
Why?
|
| Urban Health | 1 | 2020 | 101 | 0.160 |
Why?
|
| Risk Reduction Behavior | 1 | 2020 | 138 | 0.150 |
Why?
|
| Students, Medical | 1 | 2021 | 158 | 0.150 |
Why?
|
| Risk Factors | 9 | 2021 | 3994 | 0.150 |
Why?
|
| Probiotics | 2 | 2010 | 37 | 0.150 |
Why?
|
| Convergence, Ocular | 2 | 1999 | 3 | 0.150 |
Why?
|
| Betaxolol | 3 | 2003 | 3 | 0.150 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2020 | 734 | 0.150 |
Why?
|
| Hypertension | 1 | 2025 | 835 | 0.140 |
Why?
|
| Trabeculectomy | 3 | 2003 | 32 | 0.140 |
Why?
|
| Accommodation, Ocular | 5 | 2004 | 6 | 0.140 |
Why?
|
| Awareness | 1 | 2018 | 73 | 0.140 |
Why?
|
| Quality of Health Care | 1 | 2019 | 161 | 0.140 |
Why?
|
| Parathyroid Hormone | 2 | 2014 | 41 | 0.140 |
Why?
|
| Intention | 1 | 2018 | 108 | 0.130 |
Why?
|
| Mortality | 1 | 2019 | 175 | 0.130 |
Why?
|
| Registries | 2 | 2019 | 437 | 0.130 |
Why?
|
| Vulnerable Populations | 1 | 2019 | 166 | 0.130 |
Why?
|
| Social Class | 1 | 2019 | 291 | 0.130 |
Why?
|
| Attitude to Health | 1 | 2019 | 338 | 0.120 |
Why?
|
| Medicare | 1 | 2019 | 332 | 0.120 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2003 | 54 | 0.120 |
Why?
|
| Macular Edema | 1 | 2015 | 5 | 0.120 |
Why?
|
| Papillomavirus Vaccines | 1 | 2018 | 174 | 0.120 |
Why?
|
| Follow-Up Studies | 6 | 2020 | 1067 | 0.110 |
Why?
|
| Dexamethasone | 1 | 2015 | 55 | 0.110 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2015 | 62 | 0.110 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 590 | 0.110 |
Why?
|
| Treatment Outcome | 6 | 2015 | 1604 | 0.110 |
Why?
|
| Hypoparathyroidism | 1 | 2014 | 2 | 0.110 |
Why?
|
| Lipids | 1 | 2016 | 256 | 0.110 |
Why?
|
| Cerebral Ventricles | 1 | 2014 | 23 | 0.110 |
Why?
|
| Hydrocephalus | 1 | 2014 | 16 | 0.110 |
Why?
|
| Granisetron | 1 | 2014 | 1 | 0.110 |
Why?
|
| Antiemetics | 1 | 2014 | 8 | 0.110 |
Why?
|
| Hypocalcemia | 1 | 2014 | 4 | 0.110 |
Why?
|
| Vomiting | 1 | 2014 | 14 | 0.110 |
Why?
|
| Gastroenteritis | 1 | 2014 | 18 | 0.110 |
Why?
|
| Prednisolone | 1 | 2014 | 16 | 0.110 |
Why?
|
| Budesonide | 1 | 2014 | 5 | 0.110 |
Why?
|
| Bronchodilator Agents | 1 | 2014 | 26 | 0.110 |
Why?
|
| Diabetic Retinopathy | 1 | 2015 | 78 | 0.110 |
Why?
|
| Eye | 2 | 2005 | 77 | 0.100 |
Why?
|
| HIV Infections | 1 | 2008 | 2586 | 0.100 |
Why?
|
| Papillomavirus Infections | 1 | 2018 | 376 | 0.100 |
Why?
|
| Prospective Studies | 5 | 2019 | 1600 | 0.100 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2013 | 3 | 0.100 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2013 | 17 | 0.100 |
Why?
|
| Sexual Behavior | 1 | 2018 | 638 | 0.100 |
Why?
|
| Cerebral Hemorrhage | 1 | 2014 | 104 | 0.100 |
Why?
|
| Prognosis | 5 | 2020 | 861 | 0.100 |
Why?
|
| Saudi Arabia | 3 | 2020 | 6 | 0.100 |
Why?
|
| Visual Fields | 1 | 2003 | 76 | 0.100 |
Why?
|
| Vision Disorders | 1 | 2003 | 61 | 0.100 |
Why?
|
| Refraction, Ocular | 5 | 2005 | 48 | 0.090 |
Why?
|
| Parents | 1 | 2016 | 370 | 0.090 |
Why?
|
| Vitamin D | 1 | 2014 | 196 | 0.090 |
Why?
|
| Sex Factors | 5 | 2014 | 1028 | 0.090 |
Why?
|
| Retrospective Studies | 5 | 2021 | 2544 | 0.090 |
Why?
|
| Hunger | 1 | 2011 | 12 | 0.090 |
Why?
|
| Case-Control Studies | 2 | 2020 | 1285 | 0.090 |
Why?
|
| Calcium | 1 | 2014 | 491 | 0.090 |
Why?
|
| Dietary Fiber | 1 | 2011 | 51 | 0.090 |
Why?
|
| Aging | 1 | 2016 | 783 | 0.080 |
Why?
|
| Gene Expression | 1 | 2014 | 701 | 0.080 |
Why?
|
| Vitreous Body | 2 | 2015 | 10 | 0.080 |
Why?
|
| Energy Intake | 1 | 2011 | 164 | 0.080 |
Why?
|
| Strabismus | 2 | 2004 | 18 | 0.080 |
Why?
|
| Body Composition | 1 | 2011 | 159 | 0.080 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2010 | 8 | 0.080 |
Why?
|
| Asthma | 1 | 2014 | 416 | 0.080 |
Why?
|
| Exotropia | 1 | 1999 | 3 | 0.080 |
Why?
|
| Bifidobacterium | 1 | 2009 | 4 | 0.080 |
Why?
|
| Common Cold | 1 | 2009 | 5 | 0.080 |
Why?
|
| Carbonic Anhydrase Inhibitors | 1 | 1999 | 7 | 0.080 |
Why?
|
| Diarrhea | 1 | 2010 | 95 | 0.080 |
Why?
|
| Dietary Supplements | 1 | 2011 | 213 | 0.080 |
Why?
|
| Child, Preschool | 4 | 2016 | 1546 | 0.080 |
Why?
|
| Body Weight | 1 | 2011 | 429 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 2 | 2010 | 432 | 0.070 |
Why?
|
| Overweight | 1 | 2011 | 249 | 0.070 |
Why?
|
| Hospitals, Special | 1 | 1998 | 3 | 0.070 |
Why?
|
| Influenza, Human | 1 | 2009 | 92 | 0.070 |
Why?
|
| Optometry | 1 | 1998 | 5 | 0.070 |
Why?
|
| Prevalence | 3 | 2020 | 1612 | 0.070 |
Why?
|
| Statistics as Topic | 1 | 2008 | 123 | 0.070 |
Why?
|
| Ophthalmic Solutions | 2 | 2003 | 18 | 0.070 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2013 | 220 | 0.070 |
Why?
|
| Blood Pressure | 2 | 2021 | 666 | 0.070 |
Why?
|
| Age Factors | 3 | 2009 | 1154 | 0.060 |
Why?
|
| Severity of Illness Index | 1 | 2008 | 719 | 0.060 |
Why?
|
| Health Care Costs | 1 | 1996 | 91 | 0.060 |
Why?
|
| Fraud | 1 | 2024 | 9 | 0.060 |
Why?
|
| Salvage Therapy | 1 | 1994 | 10 | 0.050 |
Why?
|
| Single-Blind Method | 2 | 2015 | 54 | 0.050 |
Why?
|
| Drug Therapy, Combination | 2 | 2015 | 234 | 0.050 |
Why?
|
| Hodgkin Disease | 1 | 1994 | 13 | 0.050 |
Why?
|
| Research Personnel | 1 | 2025 | 206 | 0.050 |
Why?
|
| Head and Neck Neoplasms | 1 | 1995 | 81 | 0.050 |
Why?
|
| Anterior Chamber | 1 | 2004 | 12 | 0.050 |
Why?
|
| Lens, Crystalline | 1 | 2004 | 39 | 0.050 |
Why?
|
| Soft Tissue Neoplasms | 2 | 1993 | 15 | 0.050 |
Why?
|
| Cooperative Behavior | 1 | 2025 | 269 | 0.050 |
Why?
|
| Cross-Sectional Studies | 3 | 2020 | 3156 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2014 | 440 | 0.050 |
Why?
|
| DNA, Neoplasm | 2 | 1993 | 92 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2004 | 1081 | 0.050 |
Why?
|
| Laser Therapy | 2 | 2003 | 25 | 0.050 |
Why?
|
| Community-Institutional Relations | 1 | 2024 | 219 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2014 | 518 | 0.050 |
Why?
|
| Capacity Building | 1 | 2023 | 99 | 0.050 |
Why?
|
| Primary Health Care | 1 | 2025 | 380 | 0.050 |
Why?
|
| Physical Examination | 1 | 2021 | 45 | 0.040 |
Why?
|
| Focus Groups | 1 | 2024 | 423 | 0.040 |
Why?
|
| Eye Color | 1 | 2001 | 3 | 0.040 |
Why?
|
| American Heart Association | 1 | 2021 | 24 | 0.040 |
Why?
|
| Problem-Based Learning | 1 | 2021 | 42 | 0.040 |
Why?
|
| Censuses | 1 | 2021 | 28 | 0.040 |
Why?
|
| Technology | 1 | 2021 | 29 | 0.040 |
Why?
|
| Adenosine | 1 | 2020 | 62 | 0.040 |
Why?
|
| Health Education | 1 | 2024 | 363 | 0.040 |
Why?
|
| Learning | 1 | 2021 | 161 | 0.040 |
Why?
|
| Community-Based Participatory Research | 1 | 2024 | 352 | 0.040 |
Why?
|
| Preventive Health Services | 1 | 2020 | 66 | 0.040 |
Why?
|
| Breast Neoplasms | 2 | 1996 | 1723 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2021 | 389 | 0.040 |
Why?
|
| Curriculum | 1 | 2021 | 318 | 0.040 |
Why?
|
| Cities | 1 | 2019 | 79 | 0.040 |
Why?
|
| Forecasting | 1 | 2019 | 136 | 0.040 |
Why?
|
| Pregnancy | 1 | 2024 | 1772 | 0.030 |
Why?
|
| Research Design | 1 | 2020 | 385 | 0.030 |
Why?
|
| Life Style | 1 | 2020 | 334 | 0.030 |
Why?
|
| Diet | 1 | 2024 | 826 | 0.030 |
Why?
|
| Physicians | 1 | 2019 | 188 | 0.030 |
Why?
|
| Health Status | 1 | 2020 | 442 | 0.030 |
Why?
|
| Florida | 1 | 2018 | 478 | 0.030 |
Why?
|
| Cholesterol, LDL | 1 | 2016 | 73 | 0.030 |
Why?
|
| Cholesterol, HDL | 1 | 2016 | 99 | 0.030 |
Why?
|
| Logistic Models | 1 | 2019 | 1009 | 0.030 |
Why?
|
| HLA-B Antigens | 1 | 2015 | 11 | 0.030 |
Why?
|
| Health Behavior | 1 | 2020 | 575 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 1234 | 0.030 |
Why?
|
| Linkage Disequilibrium | 1 | 2015 | 86 | 0.030 |
Why?
|
| Drug Implants | 1 | 2015 | 20 | 0.030 |
Why?
|
| Tomography, Optical Coherence | 1 | 2015 | 38 | 0.030 |
Why?
|
| Flow Cytometry | 2 | 1993 | 411 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 118 | 0.030 |
Why?
|
| Exercise | 1 | 2021 | 692 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2014 | 9 | 0.030 |
Why?
|
| Universities | 1 | 2018 | 559 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2014 | 33 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2015 | 201 | 0.030 |
Why?
|
| Thyroid Function Tests | 1 | 2014 | 7 | 0.030 |
Why?
|
| Fluid Therapy | 1 | 2014 | 29 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2015 | 183 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2014 | 32 | 0.030 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2014 | 22 | 0.030 |
Why?
|
| Arabs | 1 | 2014 | 19 | 0.030 |
Why?
|
| Leiomyosarcoma | 1 | 1993 | 3 | 0.030 |
Why?
|
| Fibrosarcoma | 1 | 1993 | 8 | 0.030 |
Why?
|
| Acute Disease | 1 | 2014 | 155 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2014 | 206 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2014 | 128 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2014 | 260 | 0.030 |
Why?
|
| Survival Analysis | 2 | 1995 | 368 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 116 | 0.020 |
Why?
|
| Leukemia, Hairy Cell | 1 | 1993 | 3 | 0.020 |
Why?
|
| Lectins | 1 | 1993 | 19 | 0.020 |
Why?
|
| Sarcoma | 1 | 1993 | 11 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 1063 | 0.020 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 1993 | 11 | 0.020 |
Why?
|
| Lactones | 1 | 1993 | 23 | 0.020 |
Why?
|
| Genotype | 1 | 2015 | 800 | 0.020 |
Why?
|
| Vitamin D Deficiency | 1 | 2014 | 107 | 0.020 |
Why?
|
| Alleles | 1 | 2014 | 352 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2014 | 575 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 989 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2014 | 1759 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2003 | 173 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 1993 | 83 | 0.020 |
Why?
|
| Carcinoma | 1 | 2013 | 108 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2014 | 263 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2014 | 278 | 0.020 |
Why?
|
| Polysaccharides | 1 | 2011 | 72 | 0.020 |
Why?
|
| Infant | 1 | 2014 | 1175 | 0.020 |
Why?
|
| Antihypertensive Agents | 1 | 2003 | 287 | 0.020 |
Why?
|
| Placebos | 1 | 2010 | 41 | 0.020 |
Why?
|
| Philadelphia | 1 | 1999 | 20 | 0.020 |
Why?
|
| Time Factors | 1 | 2014 | 1857 | 0.020 |
Why?
|
| Chicago | 1 | 1999 | 31 | 0.020 |
Why?
|
| Regression Analysis | 2 | 1996 | 490 | 0.020 |
Why?
|
| Absenteeism | 1 | 2009 | 14 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 236 | 0.020 |
Why?
|
| Drug Utilization | 1 | 2009 | 34 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2014 | 539 | 0.020 |
Why?
|
| New York | 1 | 1998 | 93 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2009 | 587 | 0.020 |
Why?
|
| California | 1 | 1999 | 548 | 0.020 |
Why?
|
| Urban Population | 1 | 1999 | 374 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2015 | 760 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 1124 | 0.020 |
Why?
|
| Relative Value Scales | 1 | 1996 | 1 | 0.020 |
Why?
|
| Body Weights and Measures | 1 | 2005 | 25 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 1995 | 53 | 0.010 |
Why?
|
| Incidence | 1 | 1998 | 1078 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 1996 | 374 | 0.010 |
Why?
|
| Work | 1 | 2004 | 7 | 0.010 |
Why?
|
| Reading | 1 | 2004 | 13 | 0.010 |
Why?
|
| Lomustine | 1 | 1994 | 1 | 0.010 |
Why?
|
| Dacarbazine | 1 | 1994 | 6 | 0.010 |
Why?
|
| Cisplatin | 1 | 1995 | 98 | 0.010 |
Why?
|
| Prednisone | 1 | 1994 | 31 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 1994 | 53 | 0.010 |
Why?
|
| Bleomycin | 1 | 1994 | 20 | 0.010 |
Why?
|
| Biometry | 1 | 2004 | 34 | 0.010 |
Why?
|
| Anthropometry | 1 | 2004 | 97 | 0.010 |
Why?
|
| Recurrence | 1 | 1994 | 152 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2004 | 135 | 0.010 |
Why?
|
| Prescriptions | 1 | 2003 | 19 | 0.010 |
Why?
|
| Doxorubicin | 1 | 1994 | 97 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 1995 | 375 | 0.010 |
Why?
|
| Cornea | 1 | 2002 | 70 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2002 | 224 | 0.010 |
Why?
|
| Age Distribution | 1 | 2002 | 249 | 0.010 |
Why?
|
| Quality Assurance, Health Care | 1 | 2001 | 55 | 0.010 |
Why?
|
| Aneuploidy | 1 | 1993 | 24 | 0.010 |
Why?
|
| Pepsin A | 1 | 1993 | 4 | 0.010 |
Why?
|
| Pronase | 1 | 1993 | 4 | 0.010 |
Why?
|
| Bryostatins | 1 | 1993 | 3 | 0.010 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 1 | 1993 | 4 | 0.010 |
Why?
|
| Ploidies | 1 | 1993 | 7 | 0.010 |
Why?
|
| Acid Phosphatase | 1 | 1993 | 23 | 0.010 |
Why?
|
| Trypsin | 1 | 1993 | 40 | 0.010 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1993 | 43 | 0.010 |
Why?
|
| Paraffin Embedding | 1 | 1993 | 15 | 0.010 |
Why?
|
| Macrolides | 1 | 1993 | 14 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 1993 | 57 | 0.010 |
Why?
|
| Formaldehyde | 1 | 1993 | 31 | 0.010 |
Why?
|
| Cell Count | 1 | 1993 | 145 | 0.010 |
Why?
|
| Antigens, CD | 1 | 1993 | 127 | 0.010 |
Why?
|
| Protein Kinase C | 1 | 1993 | 124 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 1993 | 462 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1993 | 508 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 1993 | 638 | 0.000 |
Why?
|